Acquisition by Ann Lee of 180995 shares of Prime Medicine subject to Rule 16b-3
| PRME Etf | USD 2.65 0.25 8.62% |
About 62% of Prime Medicine,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Prime Medicine, Common suggests that many traders are alarmed. The current market sentiment, together with Prime Medicine,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Prime Medicine, Common etf news signals to limit their universe of possible portfolio assets.
Prime Medicine, etf news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Prime daily returns and investor perception about the current price of Prime Medicine, Common as well as its diversification or hedging effects on your existing portfolios.
Prime |
Filed transaction by Prime Medicine Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Prime Medicine, Fundamental Analysis
We analyze Prime Medicine,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prime Medicine, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prime Medicine, based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Prime Medicine, is currently under evaluation in earnings per share as compared to similar ETFs. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Prime Medicine, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prime Medicine, etf to make a market-neutral strategy. Peer analysis of Prime Medicine, could also be used in its relative valuation, which is a method of valuing Prime Medicine, by comparing valuation metrics with similar companies.
Peers
Prime Medicine, Related Equities
| RLAY | Relay Therapeutics | 1.90 | ||||
| BPMC | Blueprint Medicines | 0.15 | ||||
| CRSP | Crispr Therapeutics | 0.25 | ||||
| RPRX | Royalty Pharma | 0.92 | ||||
| EDIT | Editas Medicine | 1.08 | ||||
| IPSC | Century Therapeutics | 1.43 | ||||
| CRBU | Caribou Biosciences | 3.13 | ||||
| BEAM | Beam Therapeutics | 6.53 | ||||
| NTLA | Intellia Therapeutics | 6.95 | ||||
| VERV | Verve Therapeutics | 8.25 | ||||
| SANA | Sana Biotechnology | 10.07 | ||||
| DNA | Ginkgo Bioworks | 11.47 |
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.